Whether the high-grade gliomas arising in the setting of NF1 occur de novo or from transformation of a pre-existing low-grade glioma following acquisition of additional oncogenic drivers (e.g., CDKN2A deletion, ATRX mutation) remains uncertain. The gene discussed is ATRX; the disease is glioma.